85 related articles for article (PubMed ID: 4019124)
1. Increased platelet aggregation following splenectomy in patients with myeloproliferative disease.
Aviram M; Carter A; Tatarsky I; Levy Y; Brook JG
Isr J Med Sci; 1985 May; 21(5):415-7. PubMed ID: 4019124
[TBL] [Abstract][Full Text] [Related]
2. In vivo platelet release in myeloproliferative disorders.
Ireland H; Lane DA; Wolff S; Foadi M
Thromb Haemost; 1982 Aug; 48(1):41-5. PubMed ID: 6215739
[TBL] [Abstract][Full Text] [Related]
3. Abnormalities of epinephrine-induced platelet aggregation and adenine nucleotides in myeloproliferative disorders.
Yamamoto K; Sekiguchi E; Takatani O
Thromb Haemost; 1984 Dec; 52(3):292-6. PubMed ID: 6531753
[TBL] [Abstract][Full Text] [Related]
4. Decreased platelet aggregation but increased thromboxane A2 generation in polycythemia vera.
Mehta P; Mehta J; Ross M; Ostrowski N; Player D
Arch Intern Med; 1985 Jul; 145(7):1225-7. PubMed ID: 4015270
[TBL] [Abstract][Full Text] [Related]
5. Plasma fibronectin in idiopathic myelofibrosis and related chronic myeloproliferative disorders.
Hasselbalch H; Clemmensen I
Scand J Clin Lab Invest; 1987 Sep; 47(5):429-33. PubMed ID: 3477850
[TBL] [Abstract][Full Text] [Related]
6. Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity.
Gersuk GM; Carmel R; Pattamakom S; Challita PM; Rabinowitz AP; Pattengale PK
Nat Immun; 1993; 12(3):136-51. PubMed ID: 8329837
[TBL] [Abstract][Full Text] [Related]
7. Platelet survival, platelet factor-4 and bleeding time in myeloproliferative disorders.
Berild D; Hasselbalch H; Knudsen JB
Scand J Clin Lab Invest; 1987 Sep; 47(5):497-501. PubMed ID: 3477851
[TBL] [Abstract][Full Text] [Related]
8. [Platelet defects in chronic myeloproliferative disorders].
Raszeja-Specht A; Skibowska A; Kabata J; Hellmann A
Acta Haematol Pol; 1994; 25(3):253-60. PubMed ID: 7992598
[TBL] [Abstract][Full Text] [Related]
9. Biochemical and metabolic aspects of platelet dysfunction in chronic myeloproliferative disorders.
Pareti FI; Gugliotta L; Mannucci L; Guarini A; Mannucci PM
Thromb Haemost; 1982 Apr; 47(2):84-9. PubMed ID: 7101243
[TBL] [Abstract][Full Text] [Related]
10. Increased platelet adhesion under flow conditions is induced by both thalassemic platelets and red blood cells.
Goldschmidt N; Spectre G; Brill A; Zelig O; Goldfarb A; Rachmilewitz E; Varon D
Thromb Haemost; 2008 Nov; 100(5):864-70. PubMed ID: 18989531
[TBL] [Abstract][Full Text] [Related]
11. Significance of blood coagulation and platelet profiles in relation to pulmonary thrombosis in beta-thalassemia/Hb E.
Visudhiphan S; Ketsa-Ard K; Tumliang S; Piankijagum A
Southeast Asian J Trop Med Public Health; 1994 Sep; 25(3):449-56. PubMed ID: 7777905
[TBL] [Abstract][Full Text] [Related]
12. Abnormal aggregation and increased size of platelets in myeloproliferative disorders.
Cortelazzo S; Barbui T; Bassan R; Dini E
Thromb Haemost; 1980 Jun; 43(2):127-30. PubMed ID: 7455970
[TBL] [Abstract][Full Text] [Related]
13. In vitro platelet aggregation defects in patients with myeloproliferative disorders and high platelet counts: are they laboratory artefacts?
Grignani C; Noris P; Tinelli C; Barosi G; Balduini CL
Platelets; 2009 Mar; 20(2):131-4. PubMed ID: 19235056
[TBL] [Abstract][Full Text] [Related]
14. Increase in spontaneous platelet aggregation in beta-thalassemia/hemoglobin E disease: a consequence of splenectomy.
Opartkiattikul N; Funahara Y; Fucharoen S; Talalak P
Southeast Asian J Trop Med Public Health; 1992; 23 Suppl 2():36-41. PubMed ID: 1298991
[TBL] [Abstract][Full Text] [Related]
15. Blood coagulation and platelet profiles in persistent post-splenectomy thrombocytosis. The relationship to thromboembolism.
Visudhiphan S; Ketsa-Ard K; Piankijagum A; Tumliang S
Biomed Pharmacother; 1985; 39(6):264-71. PubMed ID: 4084660
[TBL] [Abstract][Full Text] [Related]
16. Platelet aggregation and platelet factor 3 activity in myeloproliferative disorders.
Tangün Y
Thromb Diath Haemorrh; 1971 Jun; 25(2):241-51. PubMed ID: 5284903
[No Abstract] [Full Text] [Related]
17. Platelets in the myeloproliferative syndrome.
Weinfeld A; Branehög I; Kutti J
Clin Haematol; 1975 Jun; 4(2):373-92. PubMed ID: 1102193
[No Abstract] [Full Text] [Related]
18. Improvement of platelet aggregation abnormalities in thrombocytosis after thrombocytopheresis.
Fabris F; Belloni M; Casonato A; Randi M; Ongaro G; Girolami A
Folia Haematol Int Mag Klin Morphol Blutforsch; 1981; 108(6):853-62. PubMed ID: 6176511
[TBL] [Abstract][Full Text] [Related]
19. [Selected parameters of blood platelet function in patients with myeloproliferative syndrome].
Zuk E
Ann Acad Med Stetin; 1998; 44():137-54. PubMed ID: 9857536
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous study of platelets and phagocytes in myeloproliferative disorders.
Laharrague PF; Corberand JX; Fillola G; Boneu BP; Pris JF
Biomed Pharmacother; 1984; 38(9-10):462-5. PubMed ID: 6597727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
